Physiologically-based toxicokinetic (PBTK) models are mathematical representations of chemical absorption, distribution, metabolism and excretion (ADME) in animals. Each parameter in a PBTK model describes a physiological, physicochemical or biochemical process that affects ADME. Distributions can be assigned to the model parameters to describe population variability and uncertainty. In this study to assess potential crop sprayer operator exposure to the herbicide haloxyfop, a permeability-limited PBTK model was constructed with parameter uncertainty and variability, and calibrated using Bayesian analysis via Markov chain Monte Carlo methods. A hierarchical statistical model was developed to reconstruct operator exposure using available measurement data: experimentally determined octanol/water partition coefficient, mouse and human toxicokinetic data as well as human biomonitoring data from seven operators who participated in a field study. A chemical risk assessment was performed by comparing the estimated systemic exposure to the acceptable operator exposure level (AOEL). The analysis suggested that in one of the seven operators, the model estimates systemic exposure to haloxyfop of 49.04 ± 10.19 SD μg/kg bw in relation to an AOEL of 5.0 μg/kg bw/day. This does not represent a safety concern as this predicted exposure is well within the 100-fold uncertainty factor applied to the No Observed Adverse Effect Level (NOAEL) in animals. In addition, given the availability of human toxicokinetic data, the 10x uncertainty factor for interspecies differences in ADME could be reduced (EFSA, 2006). Thus the AOEL could potentially be raised tenfold from 5.0 to 50.0 μg/kg bw/day.
Introduction
Haloxyfop-methyl ester is the active ingredient in various herbicide products developed as a selective post-emergence herbicide to control annual and perennial grass weeds amongst broadleaf crops. Haloxyfopmethyl ester exists as both R and S enantiomers. In plants and mammals, these enantiomers are rapidly hydrolysed to the acid haloxyfop ( Fig. 1) . In mammals, S-form haloxyfop undergoes rapid stereochemical inversion to the R form (Bartels and Smith, 1988) indicating toxicokinetic studies conducted with racemic haloxyfop or haloxyfop-P are mutually supportive. The R-enantiomer of haloxyfop is the herbicidallyactive form, while essentially no herbicidal activity is associated with the S isomer of haloxyfop (Gerwick et al., 1988) . In plants, haloxyfop-P inhibits acetyl-CoA carboxylase (ACCase) which suppresses de novo synthesis of fatty acids. In plants, conversion of the (S)-to the (R)-enantiomer does not occur (Gerwick et al., 1988) ; this step is mediated by soil microbes. Hence, commercially produced haloxyfop-R methyl ester contains a minimum of 98% of R-isomer and a maximum of 2% Senantiomer.
Haloxyfop can induce hepatotoxicity, renal toxicity, carcinogenicity, reproductive and developmental toxicity in rodents (Gorzinski et al., 1982a ,b, Hayes et al., 1983 , Nitschke et al., 1985 , Tollett et al., 1983 , Yano et al., 1984 , unexplained rabbit mortality (Hanley et al., 1985) , hepatotoxicity in Beagle dogs (Barna-Lloyd et al., 1983 , and kidney, liver and thyroid toxicity in Cynomolgus monkeys (Yano et al., 1987) . In the European Union, regulation 1107/2009 identifies that non-dietary risk assessments must be conducted for operators. Accordingly, an acceptable operator exposure limit (AOEL) of 5.0 μg/kg bw/day is established for haloxyfop (EFSA, 2009 ). This value is based on the no observed adverse effect level (NOAEL) of 500 μg/kg https://doi.org/10.1016/j.yrtph.2018.12.004 Received 19 October 2018; Received in revised form 3 December 2018; Accepted 6 December 2018 bw/day orally for the most sensitive endpoint of hepatotoxicity from a 1-year Beagle dog study (Barna-Lloyd et al., 1984) , and applying the 100-fold uncertainty factor which accounts for interspecies differences in ADME (x 10) and intraspecies (human) variability (x 10). According to Directive 97/57/EC, the AOEL is defined as 'the maximum amount of active substance to which the operator may be exposed without any adverse health effects ' (EC, 2006) . AOELs relate to the internal (absorbed) dose available for systemic distribution from any route of absorption and are expressed as internal levels (μg/kg bw/day).
Operator exposure in relation to the AOEL can be assessed through a 'forward dosimetry' approach using Predictive Operator Exposure Models (POEM), such as the Agricultural Operator Exposure Model (AOEM) developed for use in the EU (Groβkopf et al., 2013) . These models are used as tools by regulators to determine whether the pesticide should be approved for registration. They predict absorbed dose depending on the 'use scenario', such as formulation, application equipment, the degree of personal protective equipment (PPE) worn and activities performed by the operator. However POEM do not account for distribution, metabolism and excretion which affect absorbed dose and hence toxicity. Neither do they account for variability and uncertainty on absorption rates. An alternative way to assess potential operator exposure and risk is the 'reverse dosimetry' approach also known as 'exposure reconstruction', where systemic exposure is assessed using human biomonitoring (HBM) data from operators. HBM data are measurements of a species in human biofluids such as urine or blood indicative of external chemical exposure. This approach requires the use of a physiologically-based toxicokinetic (PBTK) model. PBTK models are mathematical representations of the processes affecting a chemical's in vivo toxicology: absorption, distribution, metabolism and excretion (ADME). These processes are represented by a series of differential equations that are functions of model parameters. Each parameter in a PBTK model describes a physiological, physicochemical or biochemical process. These properties distinguish PBTK models from more empirical compartment models permitting: 1) animal PBTK models to be built using in vivo animal data and then mapped onto an equivalent human PBTK model by appropriate adjustment of the model variables thereby permitting interspecies extrapolation (Wang et al., 2000) . 2) Assignment of each parameter to reflect intraspecies variability and uncertainty regarding the actual population mean value (Bois et al., 2010) , allowing tissue doses to be modelled in the target population. 3) One-to-one correspondences between model parameters and toxicokinetic processes means that many PBTK model parameter values can be determined from in vitro data allowing greater use of these models in relevant toxicological assessment. 4) Bayesian inference use to calibrate the model and reconstruct exposure from HBM data.
Bayesian inference has been widely applied across scientific disciplines for interpreting data. It is based on Bayes' theorem:
[1]
• P(X) is a probability distribution representing the state of current knowledge regarding the system of interest (i.e. the PBTK model structure and its parameter value distributions, represented by X in equation (1)) before experimental data such as in vitro, toxicokinetic and HBM data (M) are considered. Thus P(X) is termed a 'prior' probability distribution.
• The quantity P(M|X) is a likelihood function which gives the probability of obtaining M given the model and parameters, X. Thus P (M|X) represents, mathematically, the measurement process and measurement uncertainty associated with M. Higher values of P (M|X) occur when X values better explain the data. Hence the likelihood function refines the model's prior parameter distributions based on M, thereby generating a 'posterior' probability distribution P(X|M).
• P(X|M) thus represents the new knowledge state regarding the model after new data are considered.
Bayesian inference can be applied using a numerical method such as Markov Chain Monte Carlo (MCMC) sampling to calibrate PBTK models (Hastings, 1970) . The use of Bayesian inference for model calibration has two unique advantages over other calibration methods such as the 'least squares' method: the fit of each parameter is: 1) a posterior probability distribution of values (rather than a point estimate) which takes account of measurement uncertainty and variability on parameter values, and 2) informed by both experimental data and prior knowledge (Jonsson and Johanson, 2003) . The posterior parameter distributions, in conjunction with model validation procedures, define the calibrated model. Bayesian analysis can also be used to reconstruct population exposure from HBM data and quantify corresponding exposure pathways and internal dose. This has been done, for example, to assess chloroform concentrations in tap water from chloroform measurements in blood (Lyons et al., 2008) .
Experimental data which can potentially inform operator exposure reconstruction are becoming more abundant. Due to the development of high throughput systems, there is greater availability of in vitro data which can be used to populate key PBTK model parameters such as the octanol/water partition coefficient for ionisable compounds such as haloxyfop (logD). Additionally the development of human microdosing (Bauer et al., 2008) may facilitate the generation of human toxicokinetic data for use in risk assessment. Furthermore, there are regulatory initiatives for the integration of animal toxicokinetic data into Fig. 1 . Structures of haloxyfop. The product is supplied as the methyl ester that is converted to the active form haloxyfop by hydrolases in animals and plants. Once formed, haloxyfop is rapidly conjugated with glucuronic acid prior to biliary elimination. The PBTK model does not account for the hydrolysis of haloxyfop-methyl ester, and primarily deals with the major systemic metabolite (haloxyfop).
the risk assessment process of agrochemicals (Terry et al., 2016) . These multiple datasets can be analysed with a PBTK model through the use of statistical models (Bois, 2013) . The aim of this study was to perform a chemical risk assessment for operators by developing a PBTK model for haloxyfop and a hierarchical statistical model to use all available measurement data to reconstruct operator exposure: experimentally determined logD, mouse and human toxicokinetic data as well as HBM data from eight operators participating in a field study.
Methods

Systemic PBTK models
The systemic PBTK model (Fig. 2) was coded into MCSim V.5.3 which is a modelling program for Bayesian inference via MCMC simulation (Bois, 2009 ) using the Metropolis-Hastings algorithm (Hastings, 1970) . This algorithm approximates the multivariate posterior distribution from prior information and experimental data. The prior information is specified by the PBTK model in addition to its parameter values. Haloxyfop is hydrophilic and subsequently permeates through tissue basolateral membranes slowly relative to more hydrophobic chemicals. Thus, a permeability-limited tissue structure was adopted (SimulationsPlus, 2013b) ; this approach is often used when transporters are involved in chemical disposition (Jones and Rowland-Yeo, 2013 ). Simulations performed with this tissue structure exhibit low discrepancy against the commercial PBTK model GastroPlus™ V.8.5 (SimulationsPlus, 2013a). The permeability-surface area product (PStc), the parameter that describes the rate of passive diffusion across tissue basolateral membranes, was scaled according to intracellular tissue volumes (Lukacova et al., 2011) . The PBTK models were populated with mouse and human physiology taken from Brown et al. (1997) , Davies and Morris (1993) , Kyselova et al. (2003) and SimulationsPlus (2013a) . To ensure mass balance despite variability on tissue blood flows and tissue volumes, these parameters were described as fractions of cardiac output and body weight, respectively. Samples were then constrained to ensure constant cardiac output and total tissue volume during simulations (Lyons et al., 2013) :
Tissue volume = (fractional tissue volume/ ∑fractional tissue volume) x body weight [3] A single Ratp value (ratio of albumin concentration in tissue over plasma) was assumed for all tissues (0.5) except adipose (0.15), and used to calculate fraction unbound in tissue using the Poulin equation (Poulin and Theil, 2002) . GastroPlus™ was used to generate an in silico prediction for the blood/plasma concentration ratio (0.55) and subsequently used to calculate partition coefficients (Kp) though the vascular membrane into extracellular space using Poulin and Theil's extracellular method (Poulin and Theil, 2000) . Haloxyfop and its glucuronide conjugate were identified in murine bile (Smith et al., 1984) . Therefore hepatic metabolism was modelled using first-order MichaelisMenten kinetics with enterohepatic recirculation activated for haloxyfop and its glucuronide conjugate. Although reabsorption of both Whole-body PBTK model. In this model, potential exposure can occur through the dermal and inhalation routes. For simplicity, a 'rest-of-body' compartment is used to represent all other tissues modelled (adipose, brain, gonads, muscle, heart, yellow and red marrow). The model structure can be mapped onto humans or animals as required. PBTK model structure adapted from SimulationsPlus (2013b). The model code is available upon request from the lead author.
compounds from the gut is modelled, hydrolysis of the glucuronide conjugate to haloxyfop is omitted due to largely unknown activity levels of β-glucuronidase produced from gut flora.
Absorption models
The Human Respiratory Tract (HRTM) from the International Commission of Radiological Protection (ICRP, Smith et al., 2014) , gastrointestinal tract (GIT) and dermal absorption models were incorporated into the systemic PBTK model. The GIT model was a simplified version of the advanced compartmental absorption and transit (ACAT) model developed by SimulationsPlus as fewer compartments were modelled: stomach, duodenum, small intestine (replacing jejunum 1-2, ileum 1-4) and colon (SimulationsPlus, 2013b) . For haloxyfop the systemic toxicokinetics are of primary concern, and the GIT therefore primarily functions as a conduit between external dose and systemic distribution. All major gastrointestinal processes were implemented; absorption, transit, dissolution (Johnson model, Lu et al., 1993) and precipitation. HRTM was developed for all aerosol sizes of practical interest (0.6 nm -100 μm), and a median aerodynamic diameter of 5 μm was assumed for haloxyfop-methyl ester. Type F (fast absorption) was assumed as a default parameter for inhaled particulates due to an absence of information on which assignment to another absorption type could be made (ICRP, 1994) . Corresponding values for Fr (1.0 d , 2006) . The HRTM could not be fully validated as animal or human inhalation toxicokinetic data were not available for haloxyfop. For this reason HATM was adapted, so the number of compartments and transit times corresponded to the GIT model. The HATM receives phlegm from the HRTM, where absorption into blood was specified as a fraction (0.0005) of the amount entering the alimentary tract, denoted as f1. The dermal absorption model was based on the permeability-limited tissue structure available from GastroPlus™, with the addition of an upper liquid compartment to which the dermal dose was applied (Fig. 3) . The equation describing the rate of dermal permeation was adapted from Poet et al., (2002) . An additional parameter was used describing crystallisation, the formation of solid residue on the skin surface unavailable for absorption. Perkins (2004) generated 'flux constants' across the skin (μg/hr/cm 2 -skin) for haloxyfop-methyl ester, however these in vitro values are incompatible with this dermal model, as their flowthrough diffusion cell does not distinguish permeability coefficient and basolateral membrane permeability (both contribute to 'flux constant' and modelled separately here).
Measurement data
The octanol/water partition assay was performed as described in OECD (1995) and modified to resemble physiological conditions (37°C, PBS). The mouse toxicokinetic study used a single oral dose of 5 mg/kg of 14C-labelled haloxyfop (Smith et al. 1984) , whereas the human toxicokinetic study used a single oral dose of 0.2 mg/kg and separately, a single dermal dose of 0.8 mg/kg (Nolan et al. 1985) . Nolan et al. (1991) reports urinary biomonitoring measurements from eight operators using VerdictTM according to label recommendations. Details of mixing, loading, application, site conditions and amounts of haloxyfopmethyl ester found in the breathing zone and on patches attached to operator clothing are reported in Scortichini et al. (1987) . HBM data from operator initialed E.F. was omitted as analysis of creatinine data suggested this operator failed to collect all urine voided over the specified time period. Individuals J.H., M.D., D.R., J.W. and G.D. did not excrete quantifiable amounts of haloxyfop in urine, so their urine measurements were grouped together and based on one-half the limit of quantification (LOQ) for the analytical method (0.08-0.47 ng/mL). Due to the absence of actual measured data, it was assumed that; 1) the average duration of dermal exposure for operators was 108 min (Scortichini et al. 1987) , 2) the body weight of each adult operator was 70 kg (EFSA 2012), 3) the total body surface area was 16,370 cm2 (EFSA 2014), and 4) potential exposure occurred through dermal and inhalation routes. GrabItTM V.1.5 data capture software was used to extract toxicokinetic and HBM data from graphs including measurement uncertainties. The toxicokinetic data from each subject was pooled at sampled time points to create estimates of standard deviation which were assigned to plasma and urine likelihoods reflecting primarily interindividual variability. Incremental urine data were combined to give cumulative urine amounts excreted during the time course of the study, as the coded PBTK model does not calculate cumulative excretion over discrete time intervals.
Statistical model
The hierarchical statistical model was built to allow the MCMC vector to draw samples from all parameters undergoing calibration using their joint (combined) probability distribution (Gelman et al., 1996) . This was done using all haloxyfop measurement data allowing both mouse and human models to be calibrated simultaneously. In  Fig. 4 , the toxicokinetic data was aggregated at the species level thus two layers were used to encompass mouse and human toxicokinetic datasets separately, lumping interindividual variability with measurement and model uncertainty. These toxicokinetic datasets were analysed to calibrate species-specific (θ 1 ), and species non-specific PBTK model parameters (θ 2 ) which were assigned prior distributions. The latter (θ 2 ) allowed mouse toxicokinetic data to inform potential operator exposure assessment; further symbols in equation (4) (below) are defined in Fig. 4 . Whereas PStc for example is species non-specific, the gut permeability parameter is species-specific and interspecies regression equations vary making extrapolation difficult (Fagerholm et al., 1996; Zakeri-Milani et al., 2007) . The HBM data is nested within the human model such that exposure reconstruction adopts values from θ 1 and θ 2 . The data likelihood, P(E|H), becomes:
By virtue of conditional independence arguments equation two can be factorised: Fig. 3 . PBTK model for permeability-limited skin. The rate of chemical entry into the skin is given by the product of blood flow rate (Fskin) and arterial concentration (Cart). Conversely, the rate of chemical exit from the tissue is given by the product of Fskin and the venous tissue concentration (Cskin_v), which is calculated as a function of the tissue partition coefficient (Kp). The bidirectional arrows indicate the chemical can diffuse in either direction across the cellular membrane.
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Bayes' theorem, P(H|E) ∝ P(E|H) x P(H), then takes the form:
This model is presented as a directed acyclic graph (DAG) in Fig. 4 , which serves to deconvolve variabilities present in toxicokinetic data. The application of DAGs in PBTK modelling is described in detail by Bois (2013) . In brief square nodes represent known variables, whereas circular nodes represent unknown PBTK model parameters to be updated via Bayes' theorem; altogether these form the hypothesis and input to the deterministic PBTK model (f). Each iteration of the MCMC algorithm takes a sample from top level (population) parameters which are identical for all operators (θ 1 and θ 2 ) and from lower level (subject) parameters describing dermal and inhalation exposure (C u,i ). Parameter uncertainty and variability were separated for body weight, cardiac output, and fractional blood flow rates and tissue volumes (Hack et al., 2006) . These prior distributions were assigned fractional coefficients of variation (CV) of 0.50 to reflect intraindividual adult variability across different ages (20-65 years) (Hack et al., 2006) normal truncated at ± 3 standard deviations (Yang et al., 2010) . Blood flows are lesser known than tissue volumes, thus fractional coefficients of uncertainty (CU) of 0.30 were applied to blood flows, and CU of 0.20 to tissue volumes (Mezzetti et al., 2003; Hack et al., 2006) . MCMC was used to convolute prior distributions with all measurement data to obtain posterior distributions of optimised parameter values. Markov chain convergence was confirmed by running three independent chains with different random seeds and calculating potential scale reduction factors (r) for parameters using the Gelman-Rubin convergence diagnostic (Gelman and Rubin, 1992) . Chains were 'thinned' by a factor of four to minimise autocorrelation (Chiu et al., 2009) . Stationary distributions were obtained after running approximately 22,000 iterations so these initial iterations were discarded as 'burn-in'. A program was built to perform iterative simulations using parameter values sampled from the converged MCMC chain in order to assess the model's ability to fit toxicokinetic and HBM data. Subsequently, exposure in target tissues was calculated in addition to internal (absorbed) dose for comparison with the AOEL.
Selection of priors
The hyper-prior for operator exposure (Cu) was assigned a uniform distribution reflecting minimal previous knowledge on operator external exposure. Prior distributions for systemic parameters were either normally or uniformly distributed to reflect current knowledge regarding population variability based on literature review. These were left truncated at zero to ensure only positive values were selected during MCMC simulations (Bois, 2013) . Wide intervals were set for uniform distributions to reflect a high degree of uncertainty in their true values and to minimise selection bias (Yang et al., 2010) . The values of physicochemical parameters are dependent on both organismal physiology and the xenobiotic itself, therefore determining relevant priors from the literature is not straightforward. Thus uniform distributions were assigned to physicochemical parameters such as gut permeability, and biochemical parameters such as metabolic Vmax and Km (Chiu et al., 2009) , allowing the Bayesian analysis to 'speak' about these parameters. To fit the liver and kidney toxicokinetic data, active secretion was modelled therein through the use of basolateral (influx) and apical (efflux) transporters adopting Michaelis-Menten kinetics, hence uniform prior distributions were assigned to transporter Vmax and Km. The estimation of tissue-specific PStc values is not well Fig. 4 . Statistical model for analysis of mouse/ human toxicokinetic data and human biomonitoring data for haloxyfop. C: exposure concentration. C u,i : unknown exposure concentration for individual operator. f: deterministic PBTK model. HBM i data: human biomonitoring data as urine measurements from individual operators. LogD: experimental data on logarithm of octanol/water partition coefficient for haloxyfop. TK data: toxicokinetic data; t: measurement times thereof. ξ: species-specific physiology. θ 1 : species-specific PBTK model parameters. θ 2 : species non-specific PBTK model parameters. σ 1, 2, 3 : standard deviations for data variability combined with measurement and modelling uncertainty. P: prior distributions; μ, ∑: mean and standard deviation for variability thereof. Plain and dashed arrows represent statistical dependencies and exposure reconstruction, respectively. established due to poorly understood physiological aspects of tissues such as cell surface areas thus a wide prior distribution was assigned to PStc.
Results
Using the model described above, simulations were performed and the data compared with experimentally generated values to assess the accuracy of the models. A sensitivity analysis on mouse and human PBTK models is provided in Supplementary Fig. 1 .
MCMC simulations
The first calibration of the model was undertaken to mouse data and this is shown in Fig. 5 . Here the fits of the calibrated mouse PBTK model to oral mouse toxicokinetic data obtained by performing iterative simulations using parameter values sampled from the converged MCMC chain. In each case it can be seen that a good fit to the experimental data was achieved with only the early time points of the kidney concentration (Fig. 5C ) that was approximately one fold less than the experimentally determined values in the first 12 h after dosing.
After calibration of the model with mouse data it was used with human data as shown in Fig. 6 . Here the fits of the calibrated human PBTK model to human toxicokinetic data are plotted for both oral and dermal dosing. The model was used to calculate fraction absorbed through the skin in terms of the net quantity permeating into skin cells (8.1% ± 1.9 SD of dermal dose). This is outside the expected range of approximately 3% obtained under laboratory conditions, based on the amount of haloxyfop excreted in urine (Nolan et al., 1985) . The model provides good fits to plasma toxicokinetic data (Fig. 6A) following oral dosing though the fit at the early time points is slightly underestimating the plasma concentrations with the experimental data at the edge of the upper 95% limit. For the urinary levels following oral dosing there was a higher excretion at the early time points to 10 days than was predicted by the model (Fig. 6B ) but after this time there was a good fit. It is possible this is a reflection of the higher than modelled plasma levels found in the early time points that may have led to a similarly higher excretion. For dermal dosing the same relationship was seen to that with oral dosing both for the plasma concentration (Fig. 6C ) and urinary excretion (Fig. 6D) . These data may indicate that both oral and dermal dosing possibly the rate of absorption was being underestimated. Regulatory Toxicology and Pharmacology 102 (2019) 1-12 Fig . 7 shows fits of the calibrated human PBTK model to operator HBM data and corresponding estimates of actual external exposure through dermal and inhalation routes for one group of operators (Fig. 7A) and two individual operators (Fig. 7B and C) . These estimates were obtained using posterior parameter values which are consistent with the biomonitoring data, assumptions and constraints imposed by the model, exposure regimen and prior distributions. Mean estimates of actual dermal exposures were 0.79 ± 0.56 SD μg/kg bw (operators (Fig. 7E) . A full assessment of these exposure estimates requires comparison with corresponding passive biomonitoring data available in Scortichini et al., (1987) . Their measures for potential dermal exposure ranged from 3.3 to 86.3 μg/kg bw, and measures for inhalation exposure ranged from 0.020 to 0.083 μg/kg bw. Consistent with this study, the amounts of haloxyfop methyl-ester found on patches placed beneath clothing were on average five times less than those detected on the outside of clothing. Posterior means and variances, along with prior values, are provided in Tables 1 and 2 . MCMC simulations converged to r̂< 1.2 for each of the population mean and variance parameters indicating convergence (Hack et al., 2006) . The model assumes instantaneous conversion from haloxyfop-methyl ester to haloxyfop, and S-form to R form haloxyfop after absorption. Thus, the enzymatic Vmax and Km values in Table 1 represent the rate of disappearance of haloxyfop (R form) and corresponding appearance of the glucuronide conjugate. Fig. 8 shows the results of the Monte Carlo simulations for haloxyfop systemic exposure and tissue concentrations using the posterior estimates of external exposure. Mean modelled estimates of maximum systemic exposures were 0.80 ± 0.53 SD μg/kg bw (operators J.H., M.D., D.R., J.W. and G.D), 1.87 ± 1.06 SD μg/kg bw (operator J.Q.) and 49.04 ± 10.19 SD μg/kg bw (operator G.B.). The tissue exposure assessment was done for operator G.B. who was likely exposed to the greatest amount of haloxyfop methyl-ester. The fraction of haloxyfopmethyl ester absorbed through the skin was estimated from the model to be 1.10% ± 0.19 SD. Maximum tissue exposures were estimated to be 7.03 ± 1.79 SD ng/g-tissue for liver, and approximately 1.42 ± 0.51 SD ng/g-tissue for other tissues of toxicological interest (Fig. 8B) .
Uncertainty analysis
Discussion
Statistical model
Statistical models in a Bayesian framework have previously been used to calibrate PBTK models for individual animal species using multiple toxicokinetic datasets (Bois, 2000; Hack et al., 2006; Chiu et al., 2009 ). However when these animal models are extrapolated to humans in a sequential manner, covariance can be lost when parameter distributions are described as univariate instead of multivariate thereby affecting model predictions (Watanabe and Bois, 1996) . The aim of this study was to create a statistical model which would produce a single multivariate distribution from all measurement data considered. This statistical model includes mouse and human PBTK models, allowing mouse and human toxicokinetic data, as well as HBM data, to inform operator exposure reconstruction. Although toxicokinetic data has been generated in the rat, there is a significant gender difference in plasma toxicokinetics following oral dose (Smith et al., 1982) . Therefore rats were not included in this analysis as is not clear which gender would be suitable for analysis. The calibrated PBTK models generally fit mouse and human toxicokinetic data indicating functionality of the statistical model (Figs. 5-7) . The standard deviations assigned to the plotted data in Fig. 6 are generally greater than those in Fig. 5 , possibly a result of greater inter-individual physiological variability affecting ADME processes in the volunteers versus inbred mice. Fits to dermal toxicokinetic data were suboptimal by approximately one fold (Fig. 6) as different groups were used for oral and dermal exposures (Nolan et al. 1985) , but for simplicity were aggregated with identical physiology in the model. It is unclear whether the model accurately distinguished between inhalation and dermal exposure for operators, however estimates for potential external exposure were within the suitable range (discussed below). Furthermore, exposure reconstruction performed assuming only dermal exposure produced worse fits to the operator HBM data (not shown), indicating that exposure as modelled occurs through an additional route. Tables 1 and 2 indicate the toxicokinetic data used for model calibration was informative for several parameters assigned uniform distributions. This includes PStc, whose posterior distribution may be accurate given multiple toxicokinetic datasets were used in the analysis. This is advantageous because in vitro assays are currently unavailable for measuring this PBTK model parameter. The toxicokinetic data was not informative for liver enzyme Km and basolateral transporter Km for example, as posteriors were equivalent to their priors. This may be an example of parameter 'non-identifiability' described elsewhere (Bernillon and Bois, 2000) . Briefly, if X = a/b and neither a or b appear elsewhere in the PBTK model code (in this case), then there are many possibilities for a and b to make X. Because the MCMC algorithm cannot 'identify' a or b (only X), it may be necessary in future to assign a prior distribution to Vmax/Km (X), rather than each parameter individually. Posterior distributions of fractional blood flow rates and tissue volumes are generally consistent with their prior distributions (Table 2) , Cooper et al. Regulatory Toxicology and Pharmacology 102 (2019) 1-12 indicating the model structure is a good representation of the biological system it is intended to represent, and the toxicokinetic data is generally without inconsistencies. The outcome of the sensitivity analysis ( Supplementary Fig. 1 ) shows several model parameters considered to be sensitive (sensitivity coefficient ≥ 0.1). These parameters include the rate of residue crystallisation on skin and the blood/plasma concentration ratio. Further work could acquire additional in vitro data to refine the prior distributions assigned to these parameters.
Prior and posterior distributions
Risk assessment
Mean model estimates of maximum systemic exposure for all operators assessed except G.B. are below the AOEL of 5.0 μg/kg bw/day indicating minimal toxicological risk (Fig. 8) . However, the mean estimate of maximum systemic exposure for operator G.B., derived from his urinary excretion data, is approximately ten times greater than the AOEL indicating there may be a potential toxicological risk. The relatively high potential liver exposures may result from hepatic transporter activity causing sequestration, indicating a potential mechanism for observed hepatotoxicity in rodents, Beagle dogs (Barna-Lloyd et al., 1983 and Cynomolgus monkeys (Yano et al., 1987) . Previous estimates for amounts of haloxyfop-methyl ester absorbed for operators J.Q. and G.B. are 0.33 and 1.40 μg/kg bw respectively (Nolan et al., 1991) , according to a compartmental toxicokinetic model (Nolan et al., 1985) . Estimates obtained here are substantially greater which reflects the different modelling and statistical approaches utilised. It is unclear why operator G.B. excreted the most haloxyfop since air and patch data suggests his external exposure was similar to other operators (Scortichini et al., 1987) . Despite this, Fig. 8 Regulatory Toxicology and Pharmacology 102 (2019) 1-12 this indicates that operator G.B. possibly did not follow recommended exposure reduction measures in a manner similar to other operators. This may include lack of compliance with PPE and hand-washing postapplication, which may have contributed to possible contamination of collected urine samples with dermal residues of the test material. Given the availability of human toxicokinetic data (and no adverse effects observed at the dose levels tested), the 10x uncertainty factor for interspecies differences in ADME could be reduced (EFSA, 2006) . Thus the AOEL could potentially be raised tenfold from 5.0 to 50.0 μg/kg bw/day. There are several limitations to this risk assessment conducted for operators. Firstly, in vitro measures of the skin permeability coefficient (distinct from basolateral membrane permeability) are required for haloxyfop-methyl ester, and should be compared with posterior values in Table 1 in order to further validate the dermal absorption model as calibrated. This may affect estimates for the fraction of haloxyfop methyl-ester absorbed through the skin, and improve the agreement with previously calculated values (Nolan et al., 1985) . Secondly, the NOAEL of 500 μg/kg on which the AOEL is based (Barna-Lloyd et al., 1983 may not be the 'true' NOAEL. There may be doses above the NOAEL which do not elicit toxicity, but are still below the lowest observed adverse effect level (LOAEL), hence the true NOAEL is likely to be higher than 500 μg/kg bw. Benchmark dosing might be useful to identify possible ranges of the 'true' NOAEL (Filipsson et al., 2003) . Lastly, the variability of operator HBM data under working conditions may not be fully explained by the choice of distributions used in the PBTK model. Further work should consider changes to cardiac output under the expected levels of physical exertion and sweat production which may influence dermal absorption. This work further demonstrates the possible utility of PBTK models to estimate potential exposure using Bayesian analysis that can account for the uncertainly in the models using multivariate parameter distributions. The experimental, toxicokinetic and human biomonitoring data, in conjunction with the modelling approaches used, allow for the reconstruction of operator exposure to haloxyfop (both internal and external). This can be used to assess the risk of toxicity based on the estimated level of internal exposure of an individual operator. The PBTK provides insight into the ADME processes which are likely to influence the internal disposition of haloxyfop in vivo, such as liver and kidney transporter activity. Follow-up experiments could be done in this respect to assess whether haloxyfop is a substrate for transporters in these tissues. The estimates of tissue exposure obtained here, that correspond with occupational exposure, provide possible concentrations at which to do further in vitro studies with to obtain experimental data for additional model parameters and to assess for example tissue response. The estimates of operator exposure to haloxyfop obtained through the modelling can be compared with other estimates of exposure available in the literature. Furthermore, the estimates may be useful for informing chemical risk management and stewardship of commercial products containing haloxyfop.
